Home' Australian Pharmacist : Australian Pharmacist June 2012 Contents PRODUCT NEWS
that it's the interruptions that cause the
biggest delays in packing. When stock is
not available, or a script is needed, the
process is delayed. Finding and returning
patient boxes and bags, counting supplies
and pausing to re-order add time and
complication to the packing process.
These disruptions are eliminated with
MedsPro, Gerard Stevens said.
The Therapeutic Goods Administration
(TGA) has approved Xarelto (rivaroxaban) for
use in two new indications: the prevention
of stroke and systemic embolism in patients
with non-valvular atrial brillation (AF) and
at least one additional risk factor for stroke;
plus the treatment of deep vein thrombosis
(DVT) and prevention of recurrent DVT and
pulmonary embolism (PE).1 The approval
across these two indication s makes Xarelto
the rst oral anticoagulant worldwide
since warfarin to span the broadest range
of indications.1 Xarelto is the rst oral
direct Factor Xa Inhibior2 to be approved
for the prevention of stroke and systemic
embolism in patients with non-valvular
AF and at least one additional risk factor
for stroke.1 In this indication, Xarelto
provides an additional treatment option
for Australians without the need for routine
blood tests to check correct dosing, dose
adjustments or dietary restrictions.1 In the
treatment of DVT and the prevention of
recurrent DVT and PE, Xarelto represents
the rst approved oral single-drug
approach.3,4 The current standard of care
for venous thromboembolism (VTE)
treatment is an injection of enoxaparin
(low molecular weight heparin), followed
by an oral vitamin K Antagonist (VKA)
(warfarin).3 Xarelto belong s to an oral
class of anticoagulants that acts by direct
selective inhibition of Factor Xa, a factor
which acts at a pivotal stage in the blood
clotting process, thereby reducing the
risk of thrombus formation.2 According
to Dr Harry Gibbs, Vascular Physician at
the Alfred Hospital, Melbourne: 'This is an
important development in anticoagulant
management. The introduction of this drug
in two new indications provides patient s
The innovative MedsPro VPC (Virtual Pill
Count), is being introduced nationally by
Webstercare for dispensing medications
into Webstercare systems and is proving
popular with pharmacists throughout
Australia. Gerard Stevens, pharmacist and
Managing Director of Webstercare said,
'The recurring comments from many of
these pharmacists are that the system
reduces packing time and reduces the
amount of working space needed. These
two things are important to the pro tability
of the pharmacy. MedsPro VPC is a 'mini'
dispensary with the most common
medications directly in front of the
packing technician. The all in one touch
screen computer guides the technician
through the packing, dispensing and script
management process -- and the barcode
veri cation supports packing accuracy.
'We developed the MedsPro VPC speci cally
so that pharmacies can signi cantly
increase their output of our Webster-paks.
Pharmacists and technicians have told us
It's all about
the evidence 1--4
Before prescribing please review full Product Information available from Pfizer
Australia. The current Product Information is available at www.pfizer.com.au
LIPITOR® (atorvastatin) 10mg, 20mg, 40mg and 80mg Tablets. Indications: Adjunct to diet in
hypercholesterolaemia. Hypertensive patients with multiple risk factors for coronary heart disease
to reduce risk of non-fatal myocardial infarction and stroke. Contraindications: Hypersensitivity to
tablet components; active liver disease or unexplained persistent elevations of serum transaminases;
pregnancy, lactation, women of child-bearing potential unless on effective contraception, concomitant
use with fusidic acid*. Precautions: Liver dysfunction: monitor liver function tests; substantial alcohol
intake, history of liver disease; myopathy, rhabdomyolysis*: monitor CK; history of renal impairment,
risk factors predisposing to renal failure secondary to rhabdomyolysis; history of haemorrhagic
stroke or lacunar infarct; interstitial lung disease; ubiquinone levels; medications that may reduce
activity/levels of steroid hormones. See PI for details. Interactions with other Medicines: Fusidic
acid; inhibitors of cytochrome P450 3A4; antacid; colestipol; OATP1B1 transporter inhibitors, e.g.
cyclosporin; erythromycin/clarithromycin; fibric acid derivatives; niacin; azole antifungals; protease
inhibitors; diltiazem hydrochloride; grapefruit juice; digoxin; oral contraceptives. See PI for details.
Adverse Effects: Dyspepsia, nausea, flatulence, diarrhoea, constipation, nasopharyngitis*, urinary
tract infection*, liver function test abnormal*, hepatic failure*, blood creatine phosphokinase increased*,
hyperglycaemia*, myalgia, arthralgia*, pain in extremity*, musculoskeletal pain*, muscle spasms*,
joint swelling*, pharyngolaryngeal pain*, epistaxis*, headache, rhabdomyolysis, bullous rash, allergic
reactions. See PI for details. Dosage and Administration: 10--80mg/day as a single dose, at any time,
with or without food. V10112. April 2012: 10mg $37.13; 20mg $50.31; 40mg $67.44; 80mg $93.64.
*Please note changes to Product Information.
References: 1. Sever PS, et al. Lancet 2003;361:1149 -- 58. 2. LaRosa JC, et al. N Engl J Med 2005;352:1425--35.
3. Colhoun HM, et al. Lancet 2004;364:685--96. 4. Cannon CP, et al. N Engl J Med 2004;350:1495--504.
5. LIPITOR® Approved Product Information. Pfizer Australia Pty Limited, ABN 50 008 422 348. Pfizer Medical
Information: 1800 675 229 www.pfizer.com.au LIPITOR*® Reg Trademark Pfizer Inc. P6252 05/12 PPU1349/AP.
PBS Information: Restricted benefit.
For use in patients that meet the criteria set out in the
General Statement for Lipid-Lowering Drugs.
Pfizer Australia Pty Limited 38--42 Wharf Road, West Ryde NSW 2114
Links Archive Australian Pharmacist July 2012 Australian Pharmacist May 2012 Navigation Previous Page Next Page